Exhaustive Study Notes on Non-Classical Neurotransmitters and Unconventional Signaling Molecules

Criteria for Neurotransmitters and Alternative Signaling Classes

• Classical Neurotransmitter Criteria:
  • Secreted directly from neurons.
  • Restricted to specific neuronal populations (not all neurons synthesize or secrete every substance).
  • Synthesis is tightly regulated, typically by a specific enzyme.
  • Produces measurable physiological effects by binding to specific, saturable receptors.
  • Released from an axon terminal or axonal varicosity in response to an action potential or depolarizing stimulus.
  • Stored in synaptic vesicles, which protects the substance from enzymatic degradation and enables quantal, packaged release upon stimulation.
  • Possesses a dedicated mechanism for signal termination, such as enzymatic degradation or plasma membrane reuptake transporters.
• Exceptions in Non-Classical Signaling:
  • Neuropeptides: Encoded directly by DNA rather than synthesized directly by enzymes, and lack dedicated synaptic reuptake or termination mechanisms.
  • Purines and Nucleosides: Include adenosine triphosphate ($\text{ATP}$) and adenosine.
  • Soluble Gases: Include nitric oxide ($\text{NO}$) and carbon monoxide ($\text{CO}$).
  • Fatty Acid Metabolites / Lipid-Derived Signals: Include platelet activating factor ($\text{PAF}$) and endocannabinoids ($\text{anandamide}$ and $2\text{-arachidonoylglycerol}$ / $2\text{-AG}$).
  • Neurotrophic Factors: Include brain-derived neurotrophic factor ($\text{BDNF}$), nerve growth factor ($\text{NGF}$), neurotrophin-3 ($\text{NT-3}$), and neurotrophin-4/5 ($\text{NT-4/5}$).
  • $\text{D}\text{-Amino Acids}$: Include $\text{D-serine}$, $\text{D-glycine}$, and $\text{D-aspartate}$.

Purine and Nucleoside Signaling (ATP and Adenosine)

• Adenosine Triphosphate ($\text{ATP}$) Characteristics:
  • Identical to the $\text{ATP}$ used for intracellular energy storage and metabolic processes.
  • Stored inside synaptic vesicles and co-released with classical neurotransmitters upon stimulus.
  • In the peripheral nervous system ($\text{PNS}$), $\text{ATP}$ is predominantly co-released with norepinephrine or acetylcholine.
  • In the central nervous system ($\text{CNS}$), $\text{ATP}$ is co-released with a wide variety of neurotransmitters.
  • Degradation Cascade: $\text{ATP}$ is an extremely short-lived signaling molecule with a half-life of $\text{< 1\,second}$. Upon synaptic release, presynaptic and postsynaptic ecto-enzymes rapidly dephosphorylate $\text{ATP}$ into adenosine diphosphate ($\text{ADP}$), then into adenosine monophosphate ($\text{AMP}$), which is further converted into adenosine.
  • Identification as Transmitters: The identification and cloning of specific genes encoding purinergic receptors for $\text{ATP}$, $\text{adenosine}$, and uridine triphosphate ($\text{UTP}$) definitively proved that purines function as active intercellular signaling molecules.
• Physiological Roles of $\text{ATP}$:
  • Released in response to cellular stress, hypoxia, mechanical trauma, or tissue inflammation.
  • Recruits microglia and macrophages to sites of tissue injury to handle debris and cellular repair.
  • Involved in nociceptive signaling pathways, specifically playing a central role in neuropathic pain (pain originating internally from neural damage rather than external stimuli).
  • Regulates respiration in response to systemic $\text{pH}$ changes; for instance, during stroke-induced acidosis, elevated $\text{ATP}$ helps alter breathing patterns to restore systemic blood oxygen levels.
  • Release Mechanism: $\text{ATP}$ release is calcium-dependent and tetrodotoxin ($\text{TTX}$)-sensitive, meaning that blocking voltage-gated sodium channels or removing extracellular calcium prevents vesicular $\text{ATP}$ release.
• Adenosine Characteristics and Functions:
  • Released primarily by highly metabolically active or stressed cells.
  • Release Mechanism: Unlike $\text{ATP}$, adenosine release is non-vesicular, calcium-independent, and $\text{TTX}$-insensitive. It exits cells directly through plasma membrane adenosine transporters when intracellular levels rise.
  • Vascular Effects: Binds to endothelial vascular cell receptors to induce blood vessel dilation, thereby increasing local blood flow, glucose, and oxygen delivery to hyperactive brain regions.
  • Neuronal Effects: Binds to inhibitory neuronal receptors to decrease firing rates and suppress presynaptic neurotransmitter release, conserving cellular $\text{ATP}$ required to maintain resting membrane potentials.
  • Sleep Regulation: Adenosine progressively accumulates in the extracellular space throughout waking hours as a byproduct of neuronal metabolism. Elevated adenosine inhibits nearby neural circuits, promoting sleepiness.
  • Pharmacology of Caffeine: Caffeine acts as a direct competitive antagonist at adenosine receptors. By blocking adenosine binding, caffeine prevents homeostatic sleep pressure.
    • Homeostatic Adaptations: Chronic blockade of adenosine receptors by caffeine leads to receptor up-regulation (the brain synthesizes additional adenosine receptors). Consequently, when caffeine wears off, the increased pool of unoccupied adenosine receptors produces a pronounced fatigue crash.
• Ethanol Modulation of Adenosine Transport:
  • The plasma membrane adenosine transporter mediates reuptake of extracellular adenosine.
  • In experimental baseline conditions ($100\%$ transport rate), dedicated adenosine transporter inhibitors suppress transport by approximately $80\%$ (leaving $20\%$ residual activity).
  • Ethanol administration inhibits the adenosine transporter in a dose-dependent manner:
    • At a low concentration of $25\,mM$, ethanol suppresses adenosine reuptake almost as effectively as dedicated pharmacological inhibitors.
    • At a high concentration of $100\,mM$, ethanol matches the $80\%$ transport blockade of dedicated inhibitors.
  • Inhibition of adenosine reuptake causes extracellular adenosine to accumulate in the synapse, enhancing inhibitory signaling and contributing to the sedative and sleep-promoting effects of alcohol.
• Postsynaptic Retrograde Adenosine Pathway:
  • Cortical glutamatergic projections release glutamate onto striatal medium spiny neurons ($\text{MSNs}$), while midbrain projections from the ventral tegmental area ($\text{VTA}$) or substantia nigra release dopamine onto the same cells.
  • Over-excitation of $\text{MSNs}$ causes intracellular adenosine accumulation, which exits non-exocytotically via plasma membrane adenosine transporters into the synaptic cleft.
  • Adenosine spills over from the postsynaptic cell to bind presynaptic adenosine receptors on incoming glutamatergic terminals.
  • This binding suppresses further presynaptic glutamate release, functioning as a non-autoreceptor negative feedback loop to protect against excitotoxicity.

Soluble Gas Transmitters (Nitric Oxide and Carbon Monoxide)

• Nitric Oxide ($\text{NO}$) Synthesis and Signaling:
  • Presynaptic glutamate release activates postsynaptic $\text{NMDA}$ receptors, causing an influx of extracellular calcium ($\text{Ca}^{2+}$).
  • $\text{Ca}^{2+}$ activates the enzyme nitric oxide synthase ($\text{NOS}$), which catalyzes the conversion of the amino acid $\text{L-arginine}$ into $\text{NO}$ gas.
  • Because $\text{NO}$ is a small lipid-soluble gas, it cannot be packaged into synaptic vesicles and freely diffuses directly across cell membranes without requiring exocytosis or membrane transporters.
  • $\text{NO}$ lacks a dedicated extracellular degradation or reuptake mechanism; its signal terminates spontaneously through chemical reaction and diffusion.
  • Intracellular Target: $\text{NO}$ diffuses into target cells and binds to guanylate cyclase, stimulating the conversion of guanosine triphosphate ($\text{GTP}$) into cyclic guanosine monophosphate ($\text{cGMP}$).
  • Increased $\text{cGMP}$ production enhances presynaptic glutamate release in a retrograde signaling cascade.
• Role of Nitric Oxide in Synaptic Plasticity:
  • Long-Term Potentiation ($\text{LTP}$) is induced experimentally by delivering high-frequency (tetanic) stimulation to presynaptic axons, resulting in sustained post-tetanic potentiation of postsynaptic responses during subsequent low-frequency stimulation.
  • $\text{NO}$ is strictly required for $\text{LTP}$ consolidation. Genetic knockout of $\text{NOS}$ abolishes $\text{LTP}$ by preventing the retrograde $\text{NO}$-mediated enhancement of presynaptic glutamate release.
• The Nitric Oxide Cloud and Transporter Inhibition:
  • $\text{NO}$ diffuses radially outward from its postsynaptic site of origin, forming a spatial gradient or cloud, with peak concentration at the center and decreasing concentrations at greater physical distances.
  • $\text{NO}$ exerts a direct inhibitory effect on plasma membrane monoamine reuptake transporters, including the dopamine transporter ($\text{DAT}$), norepinephrine transporter ($\text{NET}$), serotonin transporter ($\text{SERT}$), and $\text{GABA}$ transporter ($\text{GAT}$).
  • Monoaminergic axon varicosities located within the $\text{NO}$ cloud experience inhibited reuptake, leaving higher concentrations of monoamines in the extracellular space for longer durations. Varicosities located outside the physical boundary of the $\text{NO}$ cloud exhibit normal, uninhibited monoamine reuptake.
• Carbon Monoxide ($\text{CO}$) Signaling:
  • Synthesized in postsynaptic neurons by the enzyme heme oxygenase in response to calcium-dependent signaling events.
  • Diffuses across lipid bilayers to bind and activate guanylate cyclase, elevating $\text{cGMP}$ and stimulating presynaptic glutamate release in a manner identical to $\text{NO}$.
  • Systemic Toxicity vs. Neural Signaling: The lethal toxicity of inhaled carbon monoxide stems entirely from $\text{CO}$ outcompeting oxygen ($\text{O}_2$) for binding sites on red blood cell hemoglobin, resulting in systemic hypoxic tissue death, which is separate from its endogenous role as a gaseous neurotransmitter.

Lipid-Derived Signaling Molecules and Cannabinoids

• Lipid Derivatives and Phospholipases:
  • Synthesized directly from plasma membrane phospholipids (such as phosphatidylserine and phosphatidylethanolamine) and cholesterol.
  • Synthesized on demand by enzymatic cleavage via the phospholipase ($\text{PL}$) family of enzymes ($\text{PLA}_1$, $\text{PLA}_2$, $\text{PLC}$, $\text{PLD}$).
• Platelet Activating Factor ($\text{PAF}$):
  • Glutamate-induced calcium influx in postsynaptic cells activates $\text{PLA}_2$, which cleaves membrane lipids to generate $\text{PAF}$.
  • $\text{PAF}$ acts as a retrograde signal, diffusing out of the postsynaptic cell to bind presynaptic $\text{PAF}$ receptors, driving increased presynaptic glutamate release.
  • $\text{PLA}_2$ cleavage also generates arachidonic acid ($\text{AA}$) and docosahexaenoic acid ($\text{DHA}$).
    • $\text{DHA}$ is a fatty acid vital for infant brain development and a standard additive in infant formulas.
    • $\text{AA}$ serves as a precursor for prostaglandins, which mediate inflammatory signaling via specific prostaglandin receptors.
  • Clinical Implications in Ischemia: During stroke or cerebral ischemia, deprivation of oxygen and glucose prevents $\text{ATP}$ synthesis, causing sustained neuronal hyper-depolarization. This triggers massive, toxic glutamate release and over-activation of $\text{PLA}_2$ and $\text{PAF}$. Pharmacological blockade of $\text{PAF}$ receptors reduces excitotoxic neuronal loss following stroke or $\text{HIV}$-induced neurotoxicity.
• Endocannabinoids:
  • Endogenous lipid ligands that activate cannabinoid receptors (the target of exogenous phytocannabinoids like $\Delta^9\text{-THC}$ and $\text{CBD}$).
  • Major endogenous cannabinoids include anandamide ($\text{AEA}$) and $2\text{-arachidonoylglycerol}$ ($2\text{-AG}$).
  • Synthesis: Produced on demand following calcium influx through activation of phospholipase D ($\text{PLD}$); they are not stored in vesicles due to their lipophilic nature.
  • Retrograde Mechanism:
    • Depolarization and calcium entry into pyramidal neuron cell bodies or dendrites activates $\text{PLD}$ to produce $2\text{-AG}$ or anandamide.
    • $\text{Endocannabinoids}$ diffuse backward across the synaptic cleft to bind presynaptic cannabinoid ($\text{CB}_1$) receptors.
    • Binding to $\text{CB}_1$ receptors on glutamatergic terminals inhibits presynaptic glutamate release (reducing excitation).
    • Binding to $\text{CB}_1$ receptors on $\text{GABA}$ergic interneuron terminals inhibits presynaptic $\text{GABA}$ release (reducing inhibition, causing disinhibition).
  • Role in Plasticity: Endocannabinoids regulate circuit excitability in the hippocampus and cortex, mediating both Long-Term Potentiation ($\text{LTP}$) and Long-Term Depression ($\text{LTD}$). Exogenous cannabinoid exposure disrupts endogenous $\text{CB}_1$ receptor dynamics, impairing memory consolidation and producing cognitive deficits.

Neuroactive Steroids and D-Amino Acids

• Neuroactive Steroids:
  • Synthesized locally in astrocytes from cholesterol precursors originating in plasma or mitochondrial membranes.
  • Include molecules such as pregnenolone, progesterone, testosterone, estradiol, pregnenolone sulfate, $\text{DHEA}$, allopregnanolone, and 5\text{\alpha},3\text{\alpha-pregnanolone}.
  • Mechanism of Action: Direct allosteric modulation of ligand-gated ionotropic neurotransmitter receptors by binding to distinct sites separate from primary neurotransmitter binding pockets.
    • 5\text{\alpha},3\text{\alpha-pregnanolone} acts as a potent positive allosteric modulator at $\text{GABA}_A$ receptors (enhancing $\text{GABA}$-induced inhibitory currents) while having no effect on $\text{NMDA}$ or glycine receptors.
    • Pregnenolone sulfate acts as a negative allosteric modulator at $\text{GABA}_A$ receptors and a positive allosteric modulator at $\text{NMDA}$ receptors.
  • Time Scale Comparison:
    • Neuroactive Steroids: Act rapidly (onset within seconds to minutes; duration of hours) by altering ion channel gating at the membrane level.
    • Classic Steroid Hormones (e.g., Cortisol, Estradiol, Progesterone): Act slowly (onset takes hours to days; duration lasts days to months) by binding intracellular/cytoplasmic receptors that translocate to the nucleus to alter gene transcription.
• $\text{D}\text{-Amino Acids}$ as Co-Agonists:
  • While $\text{L-amino acids}$ are the standard monomers for protein synthesis, $\text{D-amino acids}$ exist in high concentrations in specific brain regions as signaling molecules.
  • $\text{D-serine}$ and $\text{D-glycine}$ serve as essential co-factors at $\text{NMDA}$ receptor complexes (historically designated as the $\text{glycine}$ binding site).
  • Astrocytic Synthesis: $\text{D-serine}$ is synthesized from $\text{L-serine}$ exclusively within astrocytes by the enzyme serine racemase.
  • Synaptic vs. Extrasynaptic NMDA Receptors:
    • Synaptic $\text{NMDA}$ Receptors: Utilize $\text{D-serine}$ (supplied by adjacent astrocytic processes in the tripartite synapse) as the primary obligate co-agonist to promote $\text{LTP}$, synaptic plasticity, and cell survival.
    • Extrasynaptic $\text{NMDA}$ Receptors: Preferentially utilize $\text{D-glycine}$ as a co-agonist, driving signaling cascades that promote excitotoxicity and programmed cell death (apoptosis).

Neurotrophic Factors

• General Characteristics of Neurotrophins:
  • Include nerve growth factor ($\text{NGF}$), brain-derived neurotrophic factor ($\text{BDNF}$), neurotrophin-3 ($\text{NT-3}$), and neurotrophin-4/5 ($\text{NT-4/5}$).
  • Encoded directly by specific genes and translated as protein precursors.
  • Stored within large dense-core vesicles (similar to neuropeptides) and released via exocytosis.
  • Lack dedicated synaptic reuptake mechanisms; exert actions by binding specific cell-surface neurotrophin tyrosine kinase receptors.
  • Essential Nature: Embryonic genetic knockout of any neurotrophin or its corresponding receptor is embryonically or postnatally lethal. Studies in adult animals require conditional knockouts that preserve early development.
• Developmental vs. Adult Signaling Models:
  • Developmental Model (Target-Derived Support): Target cells release neurotrophic factors that bind receptors on presynaptic terminals of growing axons. The ligand-receptor complex is endocytosed and retrogradely transported along the axon to the cell body, activating pro-survival gene expression. Severing the axon (axotomy) in young animals deprives the neuron of target-derived trophic support, leading to cell death.
  • Adult Model (Paracrine/Autocrine Signaling): In mature neurons, axotomy does not cause cell body death because adult neurotrophic signaling shifts primarily to paracrine (neighboring cell) and autocrine (self-stimulating) mechanisms.
• Physiological and Pathological Roles:
  • BDNF in Epilepsy and Seizures: $\text{BDNF}$ expression increases sharply during seizure activity. Elevated $\text{BDNF}$ nearly doubles the action potential firing rate of cortical neurons, increasing overall network excitability and exacerbating seizure severity.
  • BDNF in Depression: Intracellular $\text{BDNF}$ levels drop significantly during major depressive episodes. Effective antidepressant therapies restore $\text{BDNF}$ expression, which promotes structural plasticity and therapeutic recovery.
  • NGF in Pain Signaling: In the peripheral nervous system ($\text{PNS}$), exposure of nociceptive fibers ($\text{C}$ fibers and $\text{A}\delta$ fibers) to $\text{NGF}$ acts as a direct pain signal.
  • NGF in Neurodegeneration: In the central nervous system ($\text{CNS}$), $\text{NGF}$ sustains basal forebrain cholinergic neurons ($\text{BFCNs}$). $\text{BFCNs}$ selectively degenerate in early-stage Alzheimer's disease, making $\text{NGF}$ pathways a focal target for neuroprotective therapeutics.

Questions and Discussion

• Question: What is the mechanism behind caffeine mixed with alcohol (e.g., pre-mixed caffeinated alcoholic beverages or vodka mixed with energy drinks)?
  • Response: Alcohol inhibits the plasma membrane adenosine transporter, elevating extracellular adenosine and promoting sedation. Caffeine acts as a competitive antagonist at adenosine receptors, blocking adenosine from binding. Combining high doses of caffeine with alcohol prevents the brain from perceiving alcohol-induced drowsiness, enabling individuals to remain awake and consume larger quantities of alcohol.
• Question: Does caffeine making a person sleepier indicate Attention-Deficit/Hyperactivity Disorder ($\text{ADHD}$)? How does that mechanism work?
  • Response: Chronic blockade of adenosine receptors by caffeine disrupts homeostatic signaling for neuronal recovery. The brain compensates by up-regulating adenosine receptors. If caffeine fails to occupy all available receptors, or as caffeine metabolizes, adenosine rapidly binds the newly synthesized receptors. This results in an acute loss of wakefulness signaling and a pronounced fatigue crash.
• Question: Since nitric oxide suppresses reuptake transporters, could it be used pharmacologically to assist Selective Serotonin Reuptake Inhibitors ($\text{SSRIs}$)?
  • Response: Although $\text{NO}$ naturally inhibits monoamine transporters ($\text{SERT}$, $\text{DAT}$, $\text{NET}$), it is a volatile, highly diffusable soluble gas, making it extremely difficult to manipulate pharmacologically in targeted clinical applications. While genetic knockout of $\text{NOS}$ or mutation of guanylate cyclase is feasible in animal models, gas-based pharmacology remains clinically impractical.
• Question: Is carbon monoxide toxicity caused by the same mechanism that increases glutamate release?
  • Response: No. Carbon monoxide toxicity occurs because $\text{CO}$ binds to hemoglobin in red blood cells with a significantly higher affinity than oxygen, displacing oxygen binding sites and producing systemic hypoxia. Its central nervous system signaling via guanylate cyclase is a separate physiological process.
• Question: Are endocannabinoids synthesized exclusively on the presynaptic cell?
  • Response: Endocannabinoids are synthesized in response to calcium influx wherever phospholipase enzymes ($\text{PLD}$) are localized. Because phospholipases are present in highest concentrations on somatodendritic membranes, endocannabinoids are primarily produced postsynaptically and travel retrogradely to act on presynaptic axon terminals.